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A B S T R A C T
Background
Evidence from observational studies suggests that diets high in omega-3 long-chain polyunsaturated fatty acids (PUFA) may protect
people from cognitive decline and dementia. The strength of this potential protective effect has recently been tested in randomised
controlled trials.
Objectives
To assess the effects of omega-3 PUFA supplementation for the prevention of dementia and cognitive decline in cognitively healthy
older people.
Search methods
We searched ALOIS - the Cochrane Dementia and Cognitive Improvement Group’s Specialized Register on 6 April 2012 using the
terms: “omega 3”, PUFA, “fatty acids”, “fatty acid”, fish, linseed, eicosapentaenoic, docosahexaenoic.
Selection criteria
Randomised controlled trials of an omega-3 PUFA intervention which was provided for a minimum of six months to participants
aged 60 years and over who were free from dementia or cognitive impairment at the beginning of the study. Two review authors
independently assessed all trials.
Data collection and analysis
The review authors sought and extracted data on incident dementia, cognitive function, safety and adherence, either from published
reports or by contacting the investigators for original data. Data were extracted by two review authors. We calculated mean difference
(MD) or standardised mean differences (SMD) and 95% confidence intervals (CI) on an intention-to-treat basis, and summarised
narratively information on safety and adherence.
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Main results
Information on cognitive function at the start of a study was available on 4080 participants randomised in three trials. Cognitive
function data were available on 3536 participants at final follow-up.
In two studies participants received gel capsules containing either omega-3 PUFA (the intervention) or olive or sunflower oil (placebo)
for six or 24 months. In one study, participants received margarine spread for 40 months; the margarine for the intervention group
contained omega-3 PUFA. Two studies had cognitive health as their primary outcome; one study of cardiovascular disease included
cognitive health as an additional outcome.
None of the studies examined the effect of omega-3 PUFA on incident dementia. In two studies involving 3221 participants there was
no difference between the omega-3 and placebo group in mini-mental state examination score at final follow-up (following 24 or 40
months of intervention); MD -0.07 (95%CI -0.25 to 0.10). In two studies involving 1043 participants, other tests of cognitive function
such as word learning, digit span and verbal fluency showed no beneficial effect of omega-3 PUFA supplementation. Participants in
both the intervention and control groups experienced either small or no cognitive declines during the studies.
The main reported side-effect of omega-3 PUFA supplementation was mild gastrointestinal problems. Overall, minor adverse events
were reported by fewer than 15% of participants, and reports were balanced between intervention groups. Adherence to the intervention
was on average over 90% among people who completed the trials. All three studies included in this review are of high methodological
quality.
Authors’ conclusions
Direct evidence on the effect of omega-3 PUFA on incident dementia is lacking. The available trials showed no benefit of omega-3
PUFA supplementation on cognitive function in cognitively healthy older people. Omega-3 PUFA supplementation is generally well
tolerated with the most commonly reported side-effect being mild gastrointestinal problems.
Further studies of longer duration are required. Longer-term studies may identify greater change in cognitive function in study
participants which may enhance the ability to detect the possible effects of omega-3 PUFA supplementation in preventing cognitive
decline in older people.
P L A I N L A N G U A G E S U M M A R Y
Fish oils for the prevention of dementia in older people
Dementia is a progressive illness which mainly affects older people. Previous research from observational studies has suggested that
increased consumption of fish oils rich in omega-3 long-chain polyunsaturated fatty acids (omega-3 PUFA) may reduce the chance of
developing dementia, while other studies show no effect. Oily fish, such as salmon, mackerel, herring and sardines are a rich source of
omega-3 PUFA which are essential for brain development.
The authors of this review included studies where healthy participants over the age of 60 years who were cognitively healthy at the
start of the study were randomly assigned to receive extra omega-3 PUFA in their diet or a placebo (such as olive oil). The main
outcomes of interest were new cases of dementia diagnosed during the study period, cognitive decline, side-effects, and adherence to
the intervention.
The authors included three randomised controlled trials involving 3536 participants. In two studies participants were randomly assigned
to receive gel capsules containing omega-3 PUFA or olive or sunflower oil for six or 24 months. In the third study, participants were
randomly assigned to receive tubs of margarine spread for 40 months (regular margarine versus margarine fortified with omega-3
PUFA).
None of the studies examined the effect of omega-3 PUFA on new dementia cases over the study period. In two studies involving 3221
participants there was no difference between the omega-3 PUFA and placebo group in mini-mental state examination score at final
follow-up. In two studies (1043 participants), other tests of cognitive function such as word learning, digit span and verbal fluency
showed no beneficial effect of omega-3 PUFA supplementation. Participants in both the intervention and control groups experienced
little or no cognitive decline during the studies.
The main reported side-effect of omega-3 PUFA supplementation was mild gastrointestinal problems, but overall minor symptoms
were reported by fewer than 15% of participants, and people in the control group were just as likely to report symptoms as those
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receiving an omega-3 PUFA supplement. Adherence to the supplementation protocol was high in all trials with on average over 90%
of supplements being apparently consumed by trial participants. All three studies included in this review were of high methodological
quality, and so the findings are unlikely to be due to chance or bias.
The results of the available studies show no benefit for cognitive function with omega-3 PUFA supplementation among cognitively
healthy older people. Omega-3 PUFA supplements may have other health benefits, and the authors comment that consumption of fish
is recommended as part of a healthy diet.
Longer studies are required, during which greater changes in cognitive function may occur, to enable researchers to identify possible
benefits of omega-3 PUFA in preventing cognitive decline.
B A C K G R O U N D
Description of the condition
Dementia is a progressive debilitating syndrome that manifests as
loss of memory, language problems, difficulties in performing ac-
tivities of daily living and psychological changes, and care for peo-
ple with dementia imposes substantial burdens on caregivers and
healthcare systems worldwide (Burns 2009b). Dementia mostly
affects older people, but can sometimes begin in younger individu-
als. Alzheimer’s disease (AD) is the most common cause of demen-
tia (Burns 2009a). Global estimates suggest that by the year 2040
more than 80 million people will be affected with dementia, and
more than 70% of these people will live in low-income countries
(Ferri 2005). Pharmacological therapies appear to produce small
symptomatic cognitive improvements for some patients but cur-
rently appear unable to halt progression of dementia (Raina 2008).
There is significant interest in identifying modifiable risk factors
(such as lifestyle) thatmay prevent dementia. Primary among these
lifestyle factors is the potential role of dietary factors, and specifi-
cally the omega-3 long-chain polyunsaturated fatty acids (PUFA).
Description of the intervention
Omega-3 fatty acids are unsaturated fatty acids characterised by
having a final carbon-carbon double bond as the third bond from
the methyl end (the n-3 position). The omega-3 PUFA of nutri-
tional importance include alpha linolenic acid (ALA, 18:3), and
two longer chain fatty acids, eicosapentaenoic acid (EPA, 20:5),
and docosahexaenoic acid (DHA, 22:6). Omega-3 fatty acids are
essential fatty acids i.e. they cannot be synthesised afresh in hu-
mans, but there is a limited ability to form the long chain fatty
acids EPA and DHA from the shorter chain ALA. Plants provide
the primary dietary source of ALA with seeds (especially flaxseed)
and nuts (especially walnuts) being significant sources. EPA and
DHA are primarily provided in the diet by the consumption of
oily fish such as salmon, mackerel, herring and sardines.
An increasing body of scientific literature has investigated the link
between omega-3 PUFA dietary consumption or physiological
status, and measures of cognitive function or dementia. A recent
systematic review identified eight cohort studies that examined the
effect of omega-3 PUFA intake or physiological status on dementia
and AD incidence, two of which reported a reduction in the risk
of dementia or AD with increased fish consumption (Dangour
2010a).
How the intervention might work
The brain is particularly rich in fatty acids and several mechanisms
have been postulated for the possible protective role of omega-3
PUFAs in dementia. First, DHA is a key component ofmembrane
phospholipids in the brain and adequate omega-3 PUFA status
may help maintain membrane integrity and neuronal function.
Secondly, the oxidative products of PUFAs act as key cellular me-
diators of inflammation, allergy and immunity, oxidative stress,
bronchial constriction, vascular responses and thrombosis andmay
thereby influence risk especially of vascular dementia (Uauy 2006).
Third, there is a suggestion that DHA may be directly involved
in enhancing neuronal health in the aging brain through a range
of potential mechanisms (Bazan 2006; Cole 2010). And finally,
there is a growing body of evidence that DHA may modify the
expression of genes that regulate a variety of biological functions
potentially important for cognitive health, including neurogenesis
and neuronal function (Rojas 2003).
Why it is important to do this review
Dementia is a significant global public health concern and there
is a clear need to identify effective interventions to slow cognitive
decline in later life and prevent dementia. Diet may prove to be
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a major modifiable risk factor in the aetiology of dementia and
of the numerous nutrients or group of nutrients that have been
investigated, the omega-3 PUFA are frequently identified among
those with the greatest evidence base to support their potential
for clinical use (Gillette Guyonnet 2007; Luchsinger 2004). This
Cochrane review update provides the latest evidence from ran-
domised controlled trials of the effect of omega-3 PUFA supple-
mentation for the primary prevention of dementia in cognitively
healthy older people.
O B J E C T I V E S
To assess the effects of omega-3 PUFA supplementation in cogni-
tively healthy older people for:
• preventing incident dementia;
• preventing or slowing cognitive decline.
M E T H O D S
Criteria for considering studies for this review
Types of studies
• Randomised controlled trials (RCTs) were eligible for
inclusion.
In addition, the studies had to include the following characteristics.
• Pre-screening of participants for dementia (dementia cases
excluded).
• Pre-screening of participants for other cognitive
impairment (cognitive impairment cases excluded).
• The trial report described the method of randomisation.
• The study must have involved 1) only participants who
were over the age of 60 years, or 2) a subgroup of participants
who were all over age 60 and whose data were analysed and
reported separately.
• The study must have given an intervention of 1) omega-3
PUFA capsules or a placebo; or 2) a strictly enforced or provided
dietary intervention (meals) including omega-3 PUFA
supplemented foods in specific portions.
• The intervention must have been provided for 26 weeks or
180 days or longer.
Types of participants
• Participants must have been age 60 years or above, and
without dementia or cognitive impairment at the beginning of
the study.
As described in the protocol for this review (Lim 2005, p.3); “The
chief consideration for the age cut-off is to ensure a characteristic
representation of the neurodegenerative diseases that are typically
seen in older persons (such as Alzheimer’s disease), as the heteroge-
neous subset of young onset dementias are often due to underlying
illnesses which are very different in aetiologies, presentation and
rate of progression from those encountered in the elderly popula-
tion. Subjects with a diagnosis of delirium and acute confusion at
study onset will be excluded.
There should be demonstration of adequate screening to exclude
pre-existing dementia or cognitive impairment via the use of cog-
nitive instruments, dementia rating scales or psychometric tests
that have been reported in peer-reviewed journals. Subjects with
known cognitive impairment but which does not amount to de-
mentia will be excluded from this review. These include (but are
not are limited to) the following diagnostic categories: dementia
prodrome, incipient dementia, cognitive impairment no demen-
tia (CIND), mild cognitive impairment (MCI), vascular cognitive
impairment (VCI), age-associated memory impairment (AAMI),
and age associated cognitive decline (AACD).While some of these
terms were conceptually meant to characterize memory changes
reflecting a ”normal“ stage of aging, more recent data has cast
some doubt on this premise (Ritchie 2000). In particular, MCI
has been recognized as a diagnostically heterogeneous entity with
a significant progression to dementia (Petersen 2001).”
Definitions of poor cognitive health at baseline could be selected
by investigators, and could differ between research projects.
Types of interventions
• Any omega-3 PUFA intervention which involved dietary
supplementation or provided meals, versus placebo or usual diet.
Studies were excluded if the intervention consisted solely of di-
etary advice, or if the intervention was based solely on self-report
(without definitive provision of meals or dietary supplements).
Types of outcome measures
Primary outcomes
• Incident dementia of any cause as defined by accepted
international diagnostic criteria.
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Secondary outcomes
• Difference between study arms at final follow-up in
recognised measures of memory and cognitive function.
• Safety of omega-3 PUFA supplementation in older people.
• Adherence to omega-3 PUFA supplementation in older
people.
Search methods for identification of studies
There were no restrictions applied to the search.
Electronic searches
We searched ALOIS (www.medicine.ox.ac.uk/alois) - the
Cochrane Dementia and Cognitive Improvement Group’s Spe-
cialized Register on 6 April 2012. The search terms used were:
“omega 3”, PUFA, “fatty acids”, “fatty acid”, fish, linseed, eicos-
apentanoic, docosahexanoic.
ALOIS is maintained by the Trials Search Co-ordinator of the
CochraneDementia and Cognitive ImprovementGroup and con-
tains studies in the areas of dementia prevention, dementia treat-
ment and cognitive enhancement in healthy people. The studies
are identified from:
1. Monthly searches of a number of major healthcare
databases: MEDLINE, EMBASE, CINAHL, PsycINFO and
LILACS
2. Monthly searches of a number of trial registers: ISRCTN;
UMIN (Japan’s Trial Register); the WHO portal (which covers
ClinicalTrials.gov; ISRCTN; the Chinese Clinical Trials Register;
the German Clinical Trials Register; the Iranian Registry of
Clinical Trials and the Netherlands National Trials Register, plus
others)
3. Quarterly search of The Cochrane Library’s Central Register
of Controlled Trials (CENTRAL)
4. Six-monthly searches of a number of grey literature sources:
ISI Web of Knowledge Conference Proceedings; Index to
Theses; Australasian Digital Theses
To view a list of all sources searched for ALOIS see About ALOIS
on the ALOIS website (www.medicine.ox.ac.uk/alois).
Details of the search strategies used for the retrieval of reports of
trials from the healthcare databases, CENTRAL and conference
proceedings can be viewed in the ‘methods used in reviews’ sec-
tion within the editorial information about the Dementia and
Cognitive Improvement Group.
Additional searches were performed in many of the sources listed
above to cover the timeframe from the last searches performed for
ALOIS to ensure that the search for the review was as up-to-date
and as comprehensive as possible. The search strategies used can
be seen in Appendix 1.
Searching other resources
On 25 February 2011 one author (ES) contacted the following
omega-3PUFA supplementmanufacturers to request unpublished
data or information on any relevant research.
• Ocean Nutrition, Aalesund, Norway.
• Martek, Maryland, USA.
• Seven Seas, London, UK.
• Nordic Naturals, California, USA
• DSM, Basel, Switzerland.
• Pronova, Lysaker, Norway.
We received replies from DSM and Pronova which both provided
published and unpublished information, none of which was rel-
evant for inclusion in the review. Seven Seas reported that they
have not conducted any research with their products on this topic
(Seven Seas correspondence). Pronova reported that they have not
conducted any research to examine the effects of their product
Omacor on dementia (Pronova correspondence).
In March 2011 two review authors (AD and W-S L) contacted
experts in nutrition research to obtain unpublished data and in-
formation about ongoing studies, and through this method we
received information about the Geleijnse 2011 study.
Data collection and analysis
Selection of studies
Two review authors screened the search results: ES and W-S L
through June 2010; AD andW-S L from June 2010 through June
2011; and ES and AD from June 2011 through April 2012. We
then retrieved the full text of relevant records. For all potentially
relevant studies, all three review authors independently compared
the study design with the inclusion criteria for this review. AD and
W-S L assessed the suitability of information provided from fish
oil manufacturers for inclusion in the review; none was relevant.
All authors agreed on the inclusion of the Geleijnse study. There
were no disagreements related to the inclusion of studies. We then
obtained the protocol for each included study.
Data extraction and management
One review author (ES) extracted the following information from
each study.
• Report - author, year and source of publication.
• Study - study setting, sample characteristics.
• Patients - demographics, screening to exclude pre-existing
cognitive impairment or dementia, absence of acute confusion or
delirium at study onset, other concomitant medical conditions
or medications that may affect cognition.
• Research design and features - sampling mechanism,
treatment assignment mechanism, blinding, drop-out rates,
length of follow-up, pertinent design features.
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• Intervention - type, duration, dose, timing, mode of
delivery.
• Outcome - number of patients randomised, outcome
measure, estimate and standard error, adverse effects, adherence,
measurement of omega-3 PUFA status.
This information was entered into Review Manager (RevMan) by
ES;W-S L checked for accuracy.We contacted trial report authors
for additional information or clarification. All report authors were
helpful and provided unpublished data and answered our ques-
tions about the design of their study.
Assessment of risk of bias in included studies
We assessed the risk of bias in each included study according to
the guidance of the Cochrane Handbook for Systematic Reviews of
Interventions (Higgins 2011 Chapter 8.5-6). We assessed the fol-
lowing domains of trial quality.
• Sequence generation - adequate when the randomisation
sequence protects against biased allocation to the comparison
groups.
• Allocation concealment - adequate when measures are
taken to ensure that recruitment according to the randomisation
sequence is performed without knowledge of the participant’s
likely treatment group.
• Blinding (participants) - adequate when measures are taken
to prevent the participants from knowing which intervention
they received.
• Blinding (investigators) - adequate when the outcome
assessor is unaware of the participant’s allocation.
• Incomplete outcome data - adequate if study authors
reported when and why participants left the study.
• Selective outcome reporting - adequate if a study protocol
was available and all outcomes were reported in the study report.
On the basis of the above criteria, trials were given a quality rating
of ’Low risk’ (adequate), ’Unclear risk’, or ’High risk’ of bias for
each domain. A description of the reason for our rating is given.
Measures of treatment effect
Where trials had comparable outcomes, mean differences (MDs)
or standardised mean differences (SMDs), with 95% confidence
intervals (CI), were calculated using a fixed-effect model. The dif-
ference between intervention groups at final follow-up was the ef-
fect measured (Higgins 2011 section 7.7.3.1). Safety and adher-
ence were summarised narratively.
Unit of analysis issues
The participant was the unit of analysis.
Dealing with missing data
We contacted trial authors requesting missing information as
needed and received replies to all our queries. The analyses were
conducted on an intention-to-treat basis.
Assessment of heterogeneity
Clinical heterogeneity caused by differences in participant charac-
teristics is likely to beminimal as included studies only randomised
cognitively healthy older people. Heterogeneity would have been
assessed separately within trials providing meals and trials provid-
ing nutritional supplements (we considered the margarine spread
intervention in the Geleijnse study a nutritional supplement). Sta-
tistical heterogeneity was assessed using the Chi2 and I2 statistics
according to the criteria in sections 9.5-6 of the Cochrane Hand-
book for Systematic Reviews of Interventions (Higgins 2011).
Assessment of reporting biases
The study protocol was available for every trial, which enabled
assessment of reporting bias.
Data synthesis
For outcomes presented in more than one trial, MDs or SMDs
and 95% CIs were combined in a fixed-effect meta-analysis using
the inverse variance method. The van de Rest study included two
treatment groups (high dose and low dose) and for this study the
shared group (placebo) was split into two to provide two reason-
ably independent comparisons (see Cochrane Handbook for Sys-
tematic Reviews of Interventions section 16.5.4). All analyses were
conducted according to the principles of intention-to-treat.
Subgroup analysis and investigation of heterogeneity
No subgroups were explored due to inclusion of only three studies.
Sensitivity analysis
No sensitivity analysis was conducted as all included studies were
of high methodological quality.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies; Characteristics of ongoing studies.
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Results of the search
The electronic search toApril 2012 retrieved a total of 1701 results.
After de-duplication and first-assessment by Anna Noel-Storr, Tri-
als Search Coordinator of the Cochrane Dementia and Cognitive
Improvement Group, the review authors were left with 129 refer-
ences to assess further. Following assessment by two authors, 124
references were discarded, five trial reports were retrieved in full-
text for further assessment, two were included and three were ex-
cluded. Nine records were received from fish oil manufacturers but
none were relevant. Contact with researchers in the field resulted
in the inclusion of a further study. The study selection process is
outlined in Figure 1.
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Figure 1.
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Included studies
In total, we included three studies in this review. The studies are
described in the Characteristics of included studies table. Van de
Rest 2008 is included as two independent comparisons (Van de
Rest 2008 (High); Van de Rest 2008 (Mod)) (see Data synthesis
above).
Information on cognitive function at the start of the study was
available on 4080 participants randomised in three studies; cog-
nitive function data were available on 3536 participants at final
follow-up.
Van de Rest 2008 was a three-arm randomised placebo-controlled
trial involving 302 participants. Male and female potential partici-
pants aged 65 + were mainly recruited from an existing database of
volunteers with interest in participating in studies at Wageningen
University, the Netherlands. Potential participants with a Mini
Mental State Examination (MMSE) score of less than 21 out of
30 or depression, or reporting the current or recent consumption
of fish oil supplements, the consumption of more than 800 mg
EPA+DHA from fish, the consumption of four or more glasses of
alcohol per day or the current use of antidepressants or medica-
tion for dementia were excluded. The intervention period was six
months and the intervention consisted of six 900 mg soft gelatin
capsules per day containing a total of 1940 mg omega-3 LC-PU-
FAs (1093 mg EPA + 847 mg DHA) in the high-dose arm, 400
mg omega-3 LC-PUFAs (226 mg EPA + 176 mg DHA) in the
low-dose arm or high-oleic sunflower oil in the placebo arm. Cap-
sules were identical in appearance and packed in foil strips con-
taining the daily dose. Three hundred and two participants were
randomised into the study and completed a series of nurse-led pa-
per-and-pencil cognitive tests at baseline, and cognitive function
outcome data are available on 299 participants at six months. The
primary outcome was cognitive function at six months.
Dangour 2010 was a two-arm randomised placebo-controlled trial
involving 867 participants. Male and female potential participants
aged 70-79 were drawn from patient lists of 20 General Practices
in England and Wales and were pre-screened using General Prac-
tice recorded information for diabetes, dementia and significant
illness (at physician’s discretion). Potential participants underwent
a cognitive function screen (MMSE) at the recruitment appoint-
ment and those with an MMSE score of less than 24 out of 30
were excluded. Potential participants reporting the current daily
use of fish oil supplements (typically rich in omega-3 LC-PUFAs)
were excluded. The intervention period was 24 months and the
intervention consisted of two 650 mg soft gelatin capsules per day
containing a total of 700 mg marine-source omega-3 LC-PUFAs
(200 mg EPA + 500 mg DHA) in the active arm, or omega-9 rich
olive oil in the placebo arm. Capsules in the two arms were iden-
tical in appearance and packed in pots. Eight hundred and sixty-
seven participants were randomised into the study and completed
a series of nurse-led paper-and-pencil cognitive tests at baseline,
and cognitive function outcome data are available on 744 partic-
ipants at 24 months. The primary outcome was change in cogni-
tive function at 24 months.
Geleijnse 2011 was a four-arm randomised placebo-controlled
trial (incorporating a 2x2 factorial design) involving 2911 partic-
ipants. People age 60-80 who scored > 21 points on the MMSE
were eligible to take part in the trial. Cognitive impairment at
baseline was defined as a MMSE score of < 24 at baseline or use
of antidementia drugs. Participants were provided with margarine
containing either 400 mg of EPA-DHA (3:2 ratio), 2 g of ALA,
the EPA-DHA and ALA combined, or placebo margarine for 40
months. (This was a study of people who had a clinically diagnosed
myocardial infarction (heart attack) up to 10 years before the start
of the study, and the primary outcome was mortality from a subse-
quent heart attack during the study period. Study recruitment was
through cardiologists. 4,837 participants took part in the primary
study and 2911 in the omega-3 sub-study; the unpublished data
used in this review include 2493 participants who did not have
cognitive impairment or use antidementia drugs at baseline, and
who also had baseline and final MMSE scores.)
The randomisation and follow-up of participants were as follows:
Study Dangour 2010 Geleijnse 2011 Van de Rest 2008 (High)
Total number of participants
randomised
867 2911 302
Number of participants with
cognitive function data at base-
line
866 2493* 302
Randomisation group I:433
C:433
I:1866
C:627
I-High:96
I-Mod:100
C:106
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(Continued)
Number of participants with
cognitive function data at final
follow-up
744 2493 299
Randomisation group I:375
C:369
I:1866
C:627
I-High:96
I-Mod:100
C:103
Intervention Group: I
Control Group: C
*the unpublished data provided by the authors in additional Ta-
ble 1 below was for participants with cognitive function data at
baseline and final follow-up.
Excluded studies
Three studies were excluded, and the reasons are given in the
Characteristics of excluded studies table.
Risk of bias in included studies
Random sequence generation (selection bias)
There was adequate generation of the randomisation sequence in
all three trials.
Allocation
Concealment of participant allocation according to the randomi-
sation sequence was adequate in all three trials.
Blinding
All three trials adequately blinded participants and outcome asses-
sors to treatment allocation.
Incomplete outcome data
Outcome reporting was adequate in all three trials and loss to
follow-up rates were low.
Selective reporting
All the trials reported the outcomes stated in their protocols.
Other potential sources of bias
It is possible there was a healthy participant bias in the Van de
Rest 2008 study as participants were primarily recruited from a
register of people interested in taking part in research.
An overall assessment of the risk of bias can be found in Figure 2
and Figure 3.
Figure 2. ’Risk of bias’ graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies. Please note there are three studies included in the review.
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Figure 3. ’Risk of bias’ summary: review authors’ judgements about each risk of bias item for each included
study. Please note there are three studies included in the review.
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Effects of interventions
Primary outcome
None of the three included trials assessed the primary outcome of
this review i.e. omega-3 fatty acids for the primary prevention of
dementia.
Secondary outcomes
All three trials investigated the effect of omega-3 fatty acid sup-
plementation on measures of cognitive function and provided in-
formation on safety and adherence.
Cognitive function
In the Dangour 2010 and Van de Rest 2008 studies, partici-
pants were asked to complete a series of cognitive function tests
at baseline and final follow-up that assessed different cognitive
domains (i.e. memory, executive function, processing speed). In
the Geleijnse 2011 study, participants completed the MMSE at
baseline and final follow-up.
Participants in both the intervention and control groups experi-
enced little or no cognitive decline during the studies. Van de Rest
2008 found no effect of low or high dose omega-3 PUFA supple-
mentation on the primary cognitive function outcome (five listed:
Word Learning Test (used to power study), Wechsler Digit Span
Test (forward and backward), Trail Making Test, The Stroop Test,
and Fluency). Dangour 2010 found no effect of omega-3 PUFA
supplementationon the primary cognitive function outcome (Cal-
ifornia Verbal Learning Test - a test of memory) or any of the spec-
ified secondary cognitive function outcomes (z-scores of multiple
tests combined by cognitive domain). Geleijnse 2011 found no
effect of omega-3 PUFA supplementation on the MMSE.
There was sufficient similarity in the cognitive function tests used
in the trials to allow the results of the following tests to be directly
compared.
Mini-mental state examination
Participants in two studies (Dangour 2010 and Geleijnse 2011)
completed theMMSE (Folstein 1975) at baseline and final follow-
up. In the Dangour 2010 study, follow-up was after 24 months of
intervention, and final follow-up in the Geleijnse 2011 study was
after 40 months of intervention. Unpublished data (Table 1) for
the Geleijnse 2011 study were provided by the authors to enable
this analysis.
Two studies involving 3221participants testedMMSE score;mean
difference (MD) -0.07 (95% confidence interval (CI) -0.25 to
0.10) with evidence of moderate heterogeneity. Analysis 1.1
Word learning
Tests of memory assess the ability of participants to recall imme-
diately (immediate recall) or after a short delay (delayed recall) a
list of words read out to the participants, and to distinguish words
from the list from various other words (word recognition). The
word learning test used in the Van de Rest 2008 study was Van
der Elst 2005, and the Dangour 2010 study used the California
Verbal Learning Test (Delis 1987).
Two studies involving 1043 participants tested immediate recall
of a list of words; standardised mean difference (SMD) 0.01 (95%
CI -0.11 to 0.14) with no evidence of heterogeneity. Analysis 2.1
Two studies involving 1043 participants tested delayed recall of a
list of words; SMD -0.04 (95%CI -0.16 to 0.09) with no evidence
of heterogeneity. Analysis 2.2
Two studies involving 1042 participants tested word recognition
of a list of words; SMD 0.04 (95% CI -0.08 to 0.16) with no
evidence of heterogeneity. Analysis 2.3
Verbal fluency
Tests of executive function assess the ability of participants to call
out as many animal names as possible. The Dangour 2010 study
used the method described in Goodglass 1983 (name as many
animals as possible in one minute), and the Van de Rest 2008
study used the method described in Van der Elst 2006 (name as
many animals as possible which begin with the letter ’p’ in two
minutes).
Two studies involving 1042 participants tested verbal fluency;
SMD 0.06 (95% CI -0.06 to 0.18) with no evidence of hetero-
geneity. Analysis 3.1
Digit spans
Tests of executive function assess the ability of participants to re-
peat either forwards or backwards chains of numbers of increasing
length read out by the test administrator. Both the Van de Rest
2008 and Dangour 2010 studies used the digit span test from the
Wechsler adult intelligence scale (Wechsler 1981).
Two studies involving 1018 participants tested digit span for-
wards; MD 0.03 (-0.25 to 0.31) with no evidence of heterogene-
ity. Analysis 4.1
Two studies involving 1015 participants tested digit span back-
wards; MD 0.12 (-0.12 to 0.36) with evidence of moderate het-
erogeneity. Analysis 4.2
Safety of omega-3 supplementation
Participants in the Van de Rest 2008 study recorded side-effects in
their patient diary, and could report side-effects to the study nurse
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at each three-monthly visit. Gastrointestinal problems were the
most commonly reported side-effect; others included restlessness,
weight gain, feeling lifeless, blurred vision, sore throat, muscle
pain, skin irritation and poly-urination (p.433). The proportion
of participants reporting side-effects was balanced between the
intervention groups (14% in the high-dose fish oil group, 13% in
the low-dose fish oil group, and 15% in the control group).
Participants in the Dangour 2010 study were given the opportu-
nity to discuss any side-effects thought to be due to the interven-
tion at their visit with the study nurse every three months (p.6
study protocol). There were no differences in reported side-effects
between study groups; symptoms included flatulence, belching,
abdominal discomfort, loose stools and ’other’ (p.3 study report).
About 9% of participants in the fish oil arm, and 10% in the
placebo arm reported one or more side-effects.
Participants in the Geleijnse 2011 study recorded symptoms of
side-effects in their patient diary, and reported symptoms during
the annual nurse-led telephone interview and at the comprehen-
sive examination at the end of the trial (p.46 of study protocol).
About 1% of participants reported experiencing gastrointestinal
problems, and there were no differences between the study groups.
(Kromhout 2010; Table 3 of supplementary web appendix.)
Adherence to supplementation
Information on adherence to supplementation relates to 3536 par-
ticipants who completed the studies.
Participants in the Van de Rest 2008 study received capsules every
three months, and returned unconsumed capsules monthly. Par-
ticipants also recorded missed capsules in their study diary. Av-
erage adherence was 99% based on the number of returned cap-
sules, and only three participants consumed fewer than 80% of
their capsules (p.432). All participants provided blood samples at
baseline and six months, and analysis demonstrated an increase in
plasma EPA-DHA in participants in the intervention arms.
Every three months participants in the Dangour 2010 study met
with a study nurse, and were asked to bring their study capsule
container with them. New capsules were provided to participants
at each visit, and the study nurse later counted the number of
returned capsules as a measure of compliance. There was no dif-
ference between study groups in the number of capsules returned
(p.3), and adherence was high as approximately 95% of the cap-
sules given to participants over the course of the study were not re-
turned. A sub-sample of 235 participants provided blood samples
at 24 months (study final follow-up), and analysis demonstrated
an increase in EPA and DHA in participants in the intervention
arm, and higher concentrations of constituents of olive oil (n-9
oleic acid) in the placebo arm.
Adherence in the Geleijnse 2011 study was measured by collecting
any unused trial margarine during delivery of the next fresh batch,
self-report during the annual nurse-led telephone interview, self-
report in the participant’s study diary (p.45-6 of study protocol).
Overall, 91% of participants consumed the trial margarine more
than 80% of the time during the 40-month study period. A ran-
dom sample of 800 participants provided blood samples at base-
line, 1.5 and three years of follow-up, and analysis demonstrated
increases in alpha-linolenic acid and in EPA and DHA in the cor-
responding study arms.
D I S C U S S I O N
Summary of main results
Three studies involving a total of 3536 participants are included
in this review. None of the studies examined the effect of omega-
3 PUFA on incident dementia. Omega-3 PUFAs were shown to
provide nobenefit to cognitive function among cognitively healthy
older people who took a variety of cognitive tests at baseline and
final follow-up, including theMini-Mental State Examination and
tests of memory and executive function.
Overall completeness and applicability of
evidence
There is no evidence from randomised controlled trials on the ef-
fect of omega-3 PUFA on incident dementia. All of the analyses of
the effect of omega-3 PUFA supplementation on cognitive func-
tion showed no benefit. Participants in both the intervention and
control groups experienced little or no cognitive decline during the
studies. The main side-effect of omega-3 PUFA supplementation
was mild gastrointestinal problems, but symptoms were reported
by a minority of participants in all three studies. Adherence to the
intervention was high in all three studies.
Further studies of longer duration are required. Longer-term stud-
ies may identify greater change in cognitive function in study par-
ticipants which may enhance the ability to detect the possible ef-
fects of omega-3 PUFA supplementation in preventing cognitive
decline in older people.
Quality of the evidence
All three studies included in this review were of high methodolog-
ical quality. The studies involved 3536 participants and the du-
ration of the intervention period had to be over six months long
(durationwas six, 24 and 40months respectively).Where the same
or similar cognitive tests were used to assess outcomes across the
studies, no benefit for omega-3 PUFA was observed.
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Potential biases in the review process
Every effort was made to conduct this review to the highest stan-
dards recommended in the Cochrane Handbook for Systematic Re-
views of Interventions, and The Cochrane Collaboration’s Method-
ological Expectations of Cochrane Intervention Reviews criteria.
Agreements and disagreements with other
studies or reviews
A comprehensive systematic review by MacLean 2005 identified
no randomised controlled trials of cognitively healthy participants
at baseline.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
The findings of three high-quality randomised controlled trials
involving 3536 participants show that there is no benefit to cog-
nitive function from omega-3 PUFA supplementation in cogni-
tively healthy people over 60 years of age. Omega-3 PUFA may
have other health benefits. Consumption of two portions of fish
per week (of which, one should be oily) is recommended as part
of a healthy diet (SACN 2004).
Implications for research
There may be benefit in conducting future long-term trials among
populations with low dietary intakes of omega-3 PUFA.
Studies of longer duration are required to determine whether
omega-3 PUFA supplementation delays cognitive decline in older
people.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Dangour 2010
Methods Double-blind, placebo-controlled, randomised controlled trial
Participants Cognitively healthy people age 70-79.
Interventions • Intervention: 500 mg DHA + 200 mg EPA in two soft gel capsules.
• Control: olive oil in two soft gel capsules.
The duration of the intervention was 24 months.
Outcomes • Primary: ’Change in cognitive function at 24 months; determined by the
California Verbal Learning Test.’ p.4 of protocol (consistent in study report, p.2).
• Secondary: ’Cognitive performance as measured by immediate and delayed recall
of a short story, tests of prospective memory, timed letter search/cancellation task,
verbal fluency, digit span forwards and backwards, symbol digit modalities test, simple
and choice reaction time, and spatial memory.’ p.4 of protocol (consistent in study
report, p.2).
Notes The study alsomeasured retinal function, the results of which are to be reported elsewhere
Study registration number on www.clinicaltrials.com: ISRCTN 72331636
The DHA and EPA used was of marine origin.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ’Randomization was minimized by age
group (70-74 and 75-79 y) and general
practice to ensure a balance across trial
arms.’ p.2
’Research nurses telephoned a central com-
puterized randomization service to obtain
treatment-allocation codes previously gen-
erated by the trial statistician.’ p.2
Allocation concealment (selection bias) Low risk ’Research nurses telephoned a central com-
puterized randomization service to obtain
treatment-allocation codes previously gen-
erated by the trial statistician.’ p.2
Blinding (performance bias and detection
bias)
Study participants
Low risk ’Supplements were packaged into identical
pots, each containing 180 capsules, and la-
belled by staff who were not involved in the
study.’ p.2
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Dangour 2010 (Continued)
Blinding (performance bias and detection
bias)
Investigators
Low risk ’Supplements were packaged into identical
pots, each containing 180 capsules, and la-
belled by staff who were not involved in the
study.’ p.2
’All project staff were unaware of group as-
signments until the completion of the trial
and after data analysis.’ p.2
Incomplete outcome data (attrition bias)
All outcomes
Low risk ’There were no preset criteria for partici-
pant withdrawal during the trial. Partici-
pants who wished only to discontinue sup-
plementation were invited to an interview
at 24 months.’ p.3
The reasons people withdrew from the
study are presented in Figure 1, and are
balanced between arms. Outcome data was
available for 375/276 participants in the in-
tervention arm, and369/372 in the placebo
arm
Selective reporting (reporting bias) Low risk The study protocol is available. The pri-
mary and secondary outcomes are reported
in full
Other bias Low risk No major sources of bias in the study de-
sign.
Geleijnse 2011
Methods Double-blind, placebo-controlled, randomised controlled trial
Participants Cognitively healthy people age 60-80 years.
Interventions Using a 2 x 2 factorial design, participants were randomised to a dietary intervention of
margarine containing:
• 400 mg/d EPA-DHA;
• 2 g/d ALA;
• both EPA and ALA;
• placebo.
The duration of the intervention was 40 months.
Outcomes • Global cognitive function assessed through the mini-mental state examination
• Incident dementia
• Others such as: mortality from coronary heart disease (primary outcome of study)
Notes Study website: www.alphaomegatrial.com (Accessed 29 October 2011)
Study registration number on www.clinicaltrials.gov: NCT00127452
The DHA and EPA used was of marine origin.
19Omega 3 fatty acid for the prevention of cognitive decline and dementia (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Geleijnse 2011 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ’Patients were randomly assigned to daily
intake of approximately 20g of trial mar-
garines ...’ p.3
Study protocol: Section D7, page 49: ’Sim-
ple randomisation is applied, using a ran-
domization table (with a randomization ra-
tio of 1:1:1:1). The table was produced on
the computer by a random-number gener-
ator before the start of the trial, with num-
bers running from 1001 through 9999.’
Allocation concealment (selection bias) Low risk Study protocol: Section D7, page 49:
’Treatment codes (A,B,C,D) are assigned
by Unilever to four types of trial margarine
and are not known to others involved in the
trial. A table linking randomization num-
bers to treatment codes is stored in a safe,
which is only accessible by a third person
who is not involved in the Alpha Omega
Trial.’
Blinding (performance bias and detection
bias)
Study participants
Low risk ’The four different types of trial margarine
were identical in taste, odor, texture, and
color.’ p.3
’Blinding was successful, as 75% of the pa-
tients could not tell which margarine they
had used and the remaining patients were
unable to perform better than chance.’ p.6
Blinding (performance bias and detection
bias)
Investigators
Low risk ’Data were analyzed before deblinding of
treatment codes by an independent statis-
tician who used a predefined data analysis
plan.’ p.5
Incomplete outcome data (attrition bias)
All outcomes
Low risk ’Blinding was maintained throughout the
study and compliance was excellent, as re-
flected in substantial increases in plasma
EPA, DHA, and ALA in active treatment
arms. No patients were lost to follow-up,
and treatment with n-3 fatty acids had no
significant side effects.’ p.8
Selective reporting (reporting bias) Low risk The study protocol is available on the
study website: www.alphaomegatrial.com
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Geleijnse 2011 (Continued)
(Accessed 29 October 2011), and there is
no indication of selective outcome report-
ing. This review uses data which were nei-
ther primary nor secondary outcomes of
the study but were published (Geleijnse
2011). The authors provided additional
data to us upon request in October 2011
to enable a meta-analysis
Other bias Low risk No major sources of bias in the study de-
sign.
Van de Rest 2008
Methods Double-blind, placebo-controlled, randomised controlled trial
Participants People age 65 and over.
Interventions • Intervention 1: 400 mg EPA/DHA in soft gel capsules (Van de Rest 2008 (Mod).
• Intervention 2: 1800 mg EPA/DHA in soft gel capsules (Van de Rest 2008 (High).
• Placebo: sunflower oil in soft gel capsules.
The duration of the intervention was 26 weeks.
Outcomes • Primary:
◦ Cognitive function (measured at baseline and at 3 and 6 months through the
Word Learning Test, the Wechsler Digit Span Task (forward and backward), the Trail
Making Test (version A and B), the Stroop Test, and Fluency (recall of animals in 2
minutes)).
◦ Depression (measured at baseline and at 3 and 6 months through the Center
for Epidemiologic Studies Depression Scale, the Montgomery-Asberg Depression
Rating Scale, the Geriatric Depression Scale, and the Hospital Anxiety and Depression
Scale (subscale version A)).
• Secondary:
◦ Quality of life (measured at baseline and at 6 months through the
WHOQOL-BREF questionnaire).
◦ Blood samples were taken to assess: APOE-ǫ4, CRP, cholesterol,
triglycerides, haematology.
Notes The outcomes are reported in three publications.
Study registration number on www.clinicaltrials.gov: NCT00124852.
The DHA and EPA used was of marine origin.
Risk of bias
Bias Authors’ judgement Support for judgement
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Van de Rest 2008 (Continued)
Random sequence generation (selection
bias)
Low risk ’An independent person randomized sub-
jects by means of computer-generated ran-
domnumbers in stratified permuted blocks
of six. Stratification factors included age (<
and ≥69 y), sex, MMSE (< and ≥ 28),
and CES-D screening test score (< and ≥
5). Individuals were randomly allocated to
receive a daily dose of fish oil containing
either approximately 400 mg or approxi-
mately 1800mgof EPA-DHA, or a placebo
oil (high-oleic sunflower oil) for 26 weeks.
’ p.431
Allocation concealment (selection bias) Low risk ’An independent person randomized sub-
jects by means of computer-generated ran-
domnumbers in stratified permuted blocks
of six. ...Staff members and participants
were blinded toward treatment allocation
until completion of blind data analysis.’ p.
431
Blinding (performance bias and detection
bias)
Study participants
Low risk ’Capsules with fish oil or placebo oil were
indistinguishable in appearance.’ p.431
Blinding (performance bias and detection
bias)
Investigators
Low risk ’Staff members and participants were
blinded toward treatment allocation until
completion of blind data analysis.’ p.431
Incomplete outcome data (attrition bias)
All outcomes
Low risk The reasons some participants withdrew
from the study are described (p.432 and
p.436). There was minimal loss to follow-
up; 299/302 participants provided out-
come data. p.432
Selective reporting (reporting bias) Low risk The study protocol is available. The out-
comes are reported in full, but in three sep-
arate publications
Other bias Low risk ’Subjects age > 65 years were mainly re-
cruited through an existing database of vol-
unteers with interest in participating in
studies atWageningen University.’ p.431 It
is possible there was a ’healthy participant’
bias among people included in the study,
see page 9 of the protocol for further details
on recruitment
There were no other major sources of bias
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Van de Rest 2008 (Continued)
in the study design
Van de Rest 2008 (High)
Methods See Van de Rest 2008
Participants
Interventions
Outcomes
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk See Van de Rest 2008.
Allocation concealment (selection bias) Low risk -
Blinding (performance bias and detection
bias)
Study participants
Low risk -
Blinding (performance bias and detection
bias)
Investigators
Low risk -
Incomplete outcome data (attrition bias)
All outcomes
Low risk -
Selective reporting (reporting bias) Low risk -
Other bias Low risk -
Van de Rest 2008 (Mod)
Methods See Van de Rest 2008.
Participants
Interventions
Outcomes
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Van de Rest 2008 (Mod) (Continued)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk See Van de Rest 2008.
Allocation concealment (selection bias) Low risk -
Blinding (performance bias and detection
bias)
Study participants
Low risk -
Blinding (performance bias and detection
bias)
Investigators
Low risk -
Incomplete outcome data (attrition bias)
All outcomes
Low risk -
Selective reporting (reporting bias) Low risk -
Other bias Low risk -
ALA: alpha linolenic acid
APOE-ǫ4: apolipoprotein E
CRP: C-reactive protein
DHA: docosahexaenoic acid
EPA: eicosapentaenoic acid
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Johnson 2008 The study was only for 4 months, without longer follow-up. Cognitive testing was done at the beginning of
the study, but people with mild/any cognitive impairment (if there were any cases) were not excluded
Svetkey 1999 Follow-up was for less than 26 weeks. Participants were older than 22 years, but we are not able to extract data
on those over 60 years from the report
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(Continued)
Yurko-Mauro 2010 The participants were aged 55 or over. Although the authors report the participants were stratified into two
groups, ≥55 to 69 and over 70, data on the over 70 group are not presented separately in the report. No
useable information is provided in this report. The participants had diagnosed age-related cognitive decline,
so are ineligible for inclusion in this review
Characteristics of ongoing studies [ordered by study ID]
Aiken 2010
Trial name or title In older adults (60+ years) at risk for depression, can sertraline and/or omega-3 fatty acids compared with
a placebo, reduce or prevent depressive symptoms, incidence of new cases of depression and/or cognitive
decline
Methods Double-blind, placebo-controlled, randomised controlled trial
Participants Participants must have participated in the first phase of the ‘Beyond Ageing Project’ run by the Centre for
Mental Health Research at the Australian National University and have completed the 24-month follow-up/
baseline survey; and have had a score greater than 15 on the K10 depression questionnaire. Participants must
be age 60 or over
Interventions One daily oral dose of:
Intervention: Four omega-3 fatty acid capsules (2g in total: Eicosapentaenoic acid (EPA) 1200 mg + Docosa-
hexaenoic acid (DHA) 800 mg).
Placebo A: One placebo tablet (cellulose - microcrystalline).
Placebo B: One sertraline 25 mg tablet and four placebo capsules (paraffin oil)
Outcomes Primary:
• Prevention of depressive symptoms over 12 months, measured by total Kessler-10 (K10), Primary Care
Evaluation of Mental Disorders Patient Health Questionnaire-9 item (PHQ-9) and Mini International
Neuropsychiatric Interview (MINI).
Secondary:
• Cognitive decline as measured by performance on the Telephone Interview Cognitive Status -
Modified (TICS-M).
• Neuropsychological performance on processing speed (CANTAB reaction time, Trailmaking Test, Part
A), memory (CANTAB paired associate learning, Wheschler Memory Scale - Third Edition (WMS-III)
Logical Memory) and Executive Functioning (Trailmaking Part B, Verbal Fluency).
• Premorbid Intelligence Quotient (IQ) estimates (Wechsler Test of Adult Reading).
• Scores on the Mini-Mental State Examination (MMSE).
• various others.
Starting date 1/03/10
Contact information Alexandra Aiken
Beyond Ageing Project Brain & Mind
Research Institute Room 312, Building F 94
Mallet Street Camperdown, NSW 2050
Australia
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Aiken 2010 (Continued)
+612 9114 4037
aaiken@med.usyd.edu.au
Notes http://www.anzctr.org.au/ACTRN12610000032055.aspx
Danthiir 2007
Trial name or title Older People, Omega-3, and Cognitive Health (EPOCH).
(An 18 month study investigating the effects of long chain omega-3 polyunsaturated fatty acids supplemen-
tation on cognition and wellbeing in older people.)
Methods Double-blind, placebo-controlled, randomised controlled trial
Participants People between 65 and 90 years of age.
Interventions Participants will consume two capsules in the morning and two in the evening, for 18 months, of either:
• Intervention: Long chain omega-3 polyunsaturated fatty acids (450 mg DHA; 135 mg EPA).
• Placebo: Olive oil capsules.
Outcomes Primary:
• Rate of cognitive decline
• Change in well being measures
Secondary:
• Plasma fatty acid changes
• Blood pressure
• Oxidative stress
• Inflammation
Starting date 1/08/2007
Contact information Dr. Vanessa Danthiir
CSIRO Human Nutrition PO Box 10041 (Gate 13 Kintore Avenue) Adelaide BC SA 5000
Australia
+61 8 8305 0605
+61 8 83038899
vanessa.danthiir@csiro.au
Notes Published protocol: Danthiir 2007.
http://www.anzctr.org.au/ACTRN12607000278437.aspx
Vellas 2008
Trial name or title Omega-3 Fatty Acids and/or Multi-domain Intervention in the Prevention of Age-related Cognitive Decline
(MAPT)
Methods Double-blind, placebo-controlled, randomised controlled trial
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Vellas 2008 (Continued)
Participants People age 70 and over.
Interventions Participants are randomised to one of three interventions or the placebo.
Interventions:
1. Omega-3 group: 800 mg/day of docosahexaenoic acid (V0137CA nutritional supplement).
2. Omega-3 + multi-domain intervention group: 800 mg/day of docosahexaenoic acid (V0137CA) +
multi-domain intervention.
3. Placebo + multi-domain intervention group: omega-3 placebo not described + multi-domain
intervention.
Placebo:
1. Placebo omega-3 only: omega-3 placebo not described.
Note: Themulti-domain intervention includes training/information sessions in the following areas: nutrition,
physical activity, cognitive training and social activities, and preventive consultations
Outcomes Primary:
• Changes in memory function scores at 36 months determined by Gröber & Buscke test. (Time
Frame: Baseline, 6, 12, 24, 36 months.)
Secondary:
• Changes in other cognitive functions, and in functional capacities. To study the long-term safety and
tolerability of V0137 CA treatment. To study compliance and adhesion to the “multi-domain” intervention
program. (Time Frame: Baseline, 6, 12, 24, 36 months.)
Starting date May 2008
Contact information Dr. Bruno Vellas
+33 5 61 77 76 49 ext 33
vellas.b@chu-toulouse.fr
Dr. Sandrine Andrieu
+33 5 51 14 59 32 ext 33
andrieu.s@chu-toulouse.fr
Notes http://clinicaltrials.gov/ct2/show/NCT00672685
DHA: docosahexaenoic acid
EPA: eicosapentaenoic acid
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D A T A A N D A N A L Y S E S
Comparison 1. Mini-Mental State Examination Score
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 MMSE score 2 3221 Mean Difference (IV, Fixed, 95% CI) -0.07 [-0.25, 0.10]
Comparison 2. Memory - Word learning test
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Immediate recall 3 1043 Std. Mean Difference (IV, Fixed, 95% CI) 0.01 [-0.11, 0.14]
2 Delayed Recall 3 1043 Std. Mean Difference (IV, Fixed, 95% CI) -0.04 [-0.16, 0.09]
3 Word Recognition 3 1042 Std. Mean Difference (IV, Fixed, 95% CI) 0.04 [-0.08, 0.16]
Comparison 3. Verbal fluency test
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Number of animals named 3 1042 Std. Mean Difference (IV, Fixed, 95% CI) 0.06 [-0.06, 0.18]
Comparison 4. Executive Function
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Digit Span Forward 3 1018 Mean Difference (IV, Fixed, 95% CI) 0.03 [-0.25, 0.31]
2 Digit Span Backward 3 1015 Mean Difference (IV, Fixed, 95% CI) 0.12 [-0.12, 0.36]
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Analysis 1.1. Comparison 1 Mini-Mental State Examination Score, Outcome 1 MMSE score.
Review: Omega 3 fatty acid for the prevention of cognitive decline and dementia
Comparison: 1 Mini-Mental State Examination Score
Outcome: 1 MMSE score
Study or subgroup Control Omega-3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Dangour 2010 363 28.3 (2.2) 365 28.2 (1.8) 35.3 % 0.10 [ -0.19, 0.39 ]
Geleijnse 2011 627 27.56 (2.45) 1866 27.73 (2.17) 64.7 % -0.17 [ -0.39, 0.05 ]
Total (95% CI) 990 2231 100.0 % -0.07 [ -0.25, 0.10 ]
Heterogeneity: Chi?? = 2.12, df = 1 (P = 0.14); I?? =53%
Test for overall effect: Z = 0.85 (P = 0.40)
Test for subgroup differences: Not applicable
-1 -0.5 0 0.5 1
Favours Omega-3 Favours Control
Analysis 2.1. Comparison 2 Memory - Word learning test, Outcome 1 Immediate recall.
Review: Omega 3 fatty acid for the prevention of cognitive decline and dementia
Comparison: 2 Memory - Word learning test
Outcome: 1 Immediate recall
Study or subgroup Control Omega-3
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Dangour 2010 369 24.4 (6.4) 375 24.1 (6.7) 73.4 % 0.05 [ -0.10, 0.19 ]
Van de Rest 2008 (High) 51 44.8 (9.4) 96 44.9 (9.9) 13.1 % -0.01 [ -0.35, 0.33 ]
Van de Rest 2008 (Mod) 52 44.8 (9.4) 100 46.1 (10.1) 13.5 % -0.13 [ -0.47, 0.20 ]
Total (95% CI) 472 571 100.0 % 0.01 [ -0.11, 0.14 ]
Heterogeneity: Chi?? = 0.93, df = 2 (P = 0.63); I?? =0.0%
Test for overall effect: Z = 0.23 (P = 0.82)
Test for subgroup differences: Not applicable
-1 -0.5 0 0.5 1
Favours Omega-3 Favours Control
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Analysis 2.2. Comparison 2 Memory - Word learning test, Outcome 2 Delayed Recall.
Review: Omega 3 fatty acid for the prevention of cognitive decline and dementia
Comparison: 2 Memory - Word learning test
Outcome: 2 Delayed Recall
Study or subgroup Control Omega-3
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Dangour 2010 369 7.5 (3) 375 7.6 (3.2) 73.4 % -0.03 [ -0.18, 0.11 ]
Van de Rest 2008 (High) 51 9 (3.2) 96 9.1 (3.2) 13.1 % -0.03 [ -0.37, 0.31 ]
Van de Rest 2008 (Mod) 52 9 (3.2) 100 9.2 (3) 13.5 % -0.06 [ -0.40, 0.27 ]
Total (95% CI) 472 571 100.0 % -0.04 [ -0.16, 0.09 ]
Heterogeneity: Chi?? = 0.03, df = 2 (P = 0.98); I?? =0.0%
Test for overall effect: Z = 0.58 (P = 0.56)
Test for subgroup differences: Not applicable
-1 -0.5 0 0.5 1
Favours Omega-3 Favours Control
Analysis 2.3. Comparison 2 Memory - Word learning test, Outcome 3 Word Recognition.
Review: Omega 3 fatty acid for the prevention of cognitive decline and dementia
Comparison: 2 Memory - Word learning test
Outcome: 3 Word Recognition
Study or subgroup Control Omega-3
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Dangour 2010 369 37.8 (4) 374 37.6 (4.3) 73.4 % 0.05 [ -0.10, 0.19 ]
Van de Rest 2008 (High) 51 28.6 (1.7) 96 28.4 (2.1) 13.1 % 0.10 [ -0.24, 0.44 ]
Van de Rest 2008 (Mod) 52 28.6 (1.7) 100 28.7 (1.5) 13.5 % -0.06 [ -0.40, 0.27 ]
Total (95% CI) 472 570 100.0 % 0.04 [ -0.08, 0.16 ]
Heterogeneity: Chi?? = 0.50, df = 2 (P = 0.78); I?? =0.0%
Test for overall effect: Z = 0.64 (P = 0.52)
Test for subgroup differences: Not applicable
-1 -0.5 0 0.5 1
Favours Omega-3 Favours Control
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Analysis 3.1. Comparison 3 Verbal fluency test, Outcome 1 Number of animals named.
Review: Omega 3 fatty acid for the prevention of cognitive decline and dementia
Comparison: 3 Verbal fluency test
Outcome: 1 Number of animals named
Study or subgroup Control Omega-3
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Dangour 2010 369 19.5 (5.3) 374 19.1 (5.4) 73.3 % 0.07 [ -0.07, 0.22 ]
Van de Rest 2008 (High) 51 24 (5.8) 96 24.2 (5.7) 13.2 % -0.03 [ -0.37, 0.30 ]
Van de Rest 2008 (Mod) 52 24 (5.8) 100 23.6 (5.8) 13.5 % 0.07 [ -0.27, 0.40 ]
Total (95% CI) 472 570 100.0 % 0.06 [ -0.06, 0.18 ]
Heterogeneity: Chi?? = 0.34, df = 2 (P = 0.84); I?? =0.0%
Test for overall effect: Z = 0.95 (P = 0.34)
Test for subgroup differences: Not applicable
-1 -0.5 0 0.5 1
Favours Omega-3 Favours Control
Analysis 4.1. Comparison 4 Executive Function, Outcome 1 Digit Span Forward.
Review: Omega 3 fatty acid for the prevention of cognitive decline and dementia
Comparison: 4 Executive Function
Outcome: 1 Digit Span Forward
Study or subgroup Control Omega-3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Dangour 2010 355 8 (2.4) 364 7.9 (2.3) 65.0 % 0.10 [ -0.24, 0.44 ]
Van de Rest 2008 (High) 51 8.5 (2) 96 8.6 (2) 16.7 % -0.10 [ -0.78, 0.58 ]
Van de Rest 2008 (Mod) 52 8.5 (2) 100 8.6 (1.8) 18.3 % -0.10 [ -0.75, 0.55 ]
Total (95% CI) 458 560 100.0 % 0.03 [ -0.25, 0.31 ]
Heterogeneity: Chi?? = 0.45, df = 2 (P = 0.80); I?? =0.0%
Test for overall effect: Z = 0.21 (P = 0.83)
Test for subgroup differences: Not applicable
-1 -0.5 0 0.5 1
Favours Omega-3 Favours Control
31Omega 3 fatty acid for the prevention of cognitive decline and dementia (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 4.2. Comparison 4 Executive Function, Outcome 2 Digit Span Backward.
Review: Omega 3 fatty acid for the prevention of cognitive decline and dementia
Comparison: 4 Executive Function
Outcome: 2 Digit Span Backward
Study or subgroup Control Omega-3
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Dangour 2010 355 6.4 (2) 361 6.4 (2) 69.8 % 0.0 [ -0.29, 0.29 ]
Van de Rest 2008 (High) 51 6.4 (1.9) 96 5.8 (1.8) 14.9 % 0.60 [ -0.03, 1.23 ]
Van de Rest 2008 (Mod) 52 6.4 (1.9) 100 6.2 (1.8) 15.3 % 0.20 [ -0.43, 0.83 ]
Total (95% CI) 458 557 100.0 % 0.12 [ -0.12, 0.36 ]
Heterogeneity: Chi?? = 2.91, df = 2 (P = 0.23); I?? =31%
Test for overall effect: Z = 0.96 (P = 0.34)
Test for subgroup differences: Not applicable
-1 -0.5 0 0.5 1
Favours Omega-3 Favours Control
A D D I T I O N A L T A B L E S
Table 1. Unpublished data from Geleijnse 2011 study
Baseline (only thosewith follow-up
MMSE)
Final follow-up (180.2 ± 5.3 weeks)
Control Group (N = 627) Control Group (N = 627)
Mean SD Range Mean SD Range
28.32 1.54 24-30 27.56 2.45 12-30
EPA-DHA Group (N = 620) EPA-DHA Group (N = 620)
Mean SD Range Mean SD Range
28.37 1.48 24-30 27.61 2.28 18-30
ALA Group (N = 638) ALA Group (N = 638)
Mean SD Range Mean SD Range
28.42 1.37 24-30 27.72 2.20 14-30
EPA-DHA + ALA Group (N = 608) EPA-DHA + ALA Group (N = 608)
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Table 1. Unpublished data from Geleijnse 2011 study (Continued)
Mean SD Range Mean SD Range
28.42 1.39 24-30 28.42 1.39 24-30
Combined intervention groups (N =
1866)
Combined intervention groups
(N= 1866)
Mean SD Mean SD
28.40 1.41 27.73 2.17
Participants with baseline and final follow-up MMSE scores, who did not have dementia, cognitive impairment or use anti-dementia
drugs at baseline.
ALA: alpha linolenic acid
DHA: docosahexaenoic acid
EPA: eicosapentaenoic acid
MMSE: Mini Mental State Examination
SD: standard deviation
A P P E N D I C E S
Appendix 1. Search: June 2011
Source Search strategy Hits
ALOIS (www.medicine.ox.ac.uk/alois) Keyword search: “omega 3” ORPUFAOR
“fatty acids” OR “fatty acid” OR fish OR
linseed OR eicosapentanoic OR docosa-
hexanoic
June 2010:39
June 2011: 41
MEDLINE In-process and other non-
indexed citations and MEDLINE 1950-
present (Ovid SP)
1. exp *Fatty Acids, Omega-3/
2. (omega-3 or “omega 3”).mp.
3. “Polyunsaturated fatty acid*”.mp.
4. PUFA.mp.
5. (“unsaturated fatty acid*” or “essential
fatty acid*”).mp
6. EFA.ti,ab.
7. Eicosapentaenoic Acid/
June 2010:73
June 2011: 36
April 2012: 24
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(Continued)
8. “eicosapentanoic acid”.ti,ab.
9. (EPA or “ethyl-eicosapentanoic acid” or
E-EPA).mp.
10. Docosahexaenoic Acids/
11. “docosahexanoic acid*”.ti,ab.
12. DHA.ti,ab.
13. (“docosapentanoic acid*” or DPA).ti,
ab.
14. (“alpha-linolenic acid*” or ALA).ti,ab.
15. (“fish oil” or “n-3 fatty acid*” or “long
chain fatty acids”).mp
16. (“primrose oil” or “linseed oil” or “oily
fish” or “flaxseed oil”).mp
17. or/1-16
18. randomized controlled trial.pt.
19. controlled clinical trial.pt.
20. randomized.ab.
21. placebo.ab.
22. randomly.ab.
23. trial.ab.
24. groups.ab.
25. or/18-24
26. (animals not (humans and animals)).
sh.
27. 25 not 26
28. 17 and 27
29. (2008* or 2009* or 2010* or 2011*).
ed.
30. 28 and 29
31. (participant* adj2 (healthy or old* or
elderly or aged or senior)).ti,ab
32. (adult adj2 (old* or elderly or aged or
senior)).ti,ab.
33. “healthy persons”.ti,ab.
34. (cognit* or “prevent* dementia*”).mp.
35. or/31-34
36. 30 and 35
EMBASE
1980-2010 week 25 (Ovid SP)
1. exp *omega 3 fatty acid/
2. (omega-3 or “omega 3”).mp.
3. “Polyunsaturated fatty acid*”.mp.
4. PUFA.mp.
5. (“unsaturated fatty acid*” or “essential
fatty acid*”).mp
6. EFA.ti,ab.
7. icosapentaenoic acid/
8. “eicosapentanoic acid”.ti,ab.
9. (EPA or “ethyl-eicosapentanoic acid” or
E-EPA).mp.
June 2010:98
June 2011: 127
April 2012: 133
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(Continued)
10. docosahexaenoic acid/
11. “docosahexanoic acid*”.ti,ab.
12. DHA.ti,ab.
13. (“docosapentanoic acid*” or DPA).ti,
ab.
14. (“alpha-linolenic acid*” or ALA).ti,ab.
15. (“fish oil” or “n-3 fatty acid*” or “long
chain fatty acids”).mp
16. (“primrose oil” or “linseed oil” or “oily
fish” or “flaxseed oil”).mp
17. or/1-16
18. (adult adj2 (old* or elderly or aged or
senior)).ti,ab.
19. (participant* adj2 (healthy or old* or
elderly or aged or senior)).ti,ab
20. “healthy persons”.ti,ab.
21. (cognit* or “prevent* dementia*”).mp.
22. (cognit* or “prevent* dementia*” or “re-
duc* risk*”).mp.
23. *primary prevention/
24. or/18-23
25. 17 and 24
26. randomized controlled trial/
27. controlled clinical trial/
28. randomi?ed.ab.
29. placebo.ab.
30. randomly.ab.
31. trial.ab.
32. groups.ab.
33. (“double-blind*” or “single-blind*”).ti,
ab.
34. or/26-33
35. 25 and 34
36. (2009* or 2010* or 2011*).em.
37. 35 and 36
PSYCINFO
1806-June week 4 2010 (Ovid SP)
1. exp Fatty Acids/
2. (omega-3 or “omega 3”).mp.
3. “Polyunsaturated fatty acid*”.mp.
4. PUFA.mp.
5. (“unsaturated fatty acid*” or “essential
fatty acid*”).mp
6. EFA.ti,ab.
7. “eicosapentaenoic acid*”.mp.
8. (EPA or “ethyl-eicosapentanoic acid” or
E-EPA).mp.
9. “docosahexaenoic acid*”.mp.
10. DHA.ti,ab.
11. (“docosapentanoic acid*” or DPA).ti,
June 2010: 31
June 2011: 36
April 2012: 28
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ab.
12. (“alpha-linolenic acid*” or ALA).ti,ab.
13. (“fish oil” or “n-3 fatty acid*” or “long
chain fatty acids”).mp
14. (“primrose oil” or “linseed oil” or “oily
fish” or “flaxseed oil”).mp
15. or/1-14
16. (adult adj2 (old* or elderly or aged or
senior)).ti,ab.
17. (participant* adj2 (healthy or old* or
elderly or aged or senior)).ti,ab
18. “healthy persons”.ti,ab.
19. (cognit* or “prevent* dementia*”).mp.
20. (cognit* or “prevent* dementia*” or “re-
duc* risk*”).mp.
21. *Prevention/
22. or/16-21
23. 15 and 22
24. random*.ti,ab.
25. placebo*.ti,ab.
26. trial*.mp.
27. (“double-blind*” or “single-blind*”).ti,
ab.
28. or/24-27
29. 23 and 28
30. (2009* or 2010* or 2011*).up.
31. 29 and 30
CINAHL (EbscoHOST) S1 (MH “Fatty Acids+”) or (MH “Fatty
Acids, Omega 3+”)
S2 TX “fatty acid*” or fats or omega-3 or
“omega 3” or PUFA or EPA or E-EPA or
DHA or DPA or ALA
S3 TX n-3-fatty-acid* or “n-3 fatty acid*”
or “linseed oil” or “flaxseed oil” or “fish oil”
or “salmon oil” or “cod liver oil”
S4 TX “eicosapentanoic acid*” or “docosa-
hexanoic acid*” or “dosapentanoic acid*”
or “alpha-linolenic acid*” or “ethyl-eicos-
apentanoic acid*”
S5 S1 or S2 or S3 or S4
S6 (MH “Preventive Trials”)
S7 TX prevent* OR avoid* or “reduc*
ADJ2 risk*”
S8 S6 or S7
S9 S5 and S8
S10TXhealthyORnormalORelderlyOR
older
S11 S9 and S10
June 2010: 6
June 2011: 3
April 2012: 1
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S12TX random*ORplacebo*ORdouble-
blind*
S13 S11 and S12
S14 TX cognit*
S15 S13 and S14
S16 em 2009
S17 EM 2010 OR EM 2011
S18 S16 or S17
S19 S15 and S18
Web of Science with Conference Proceed-
ings (1945 to present) (ISI Web of Knowl-
edge)
#1 Topic=(“fatty acid*” OR “omega 3”OR
PUFA OR EFA OR EPA OR DHA OR
eicosapentanoic OR docosahexanoic OR
“alpha-linolenic acid” OR “fish oil*” OR
“primrose oil” OR “linseed oil”)
#2 Topic=(“prevent* dement*” OR “pre-
vent* alzheimer*” OR cognition OR cog-
nitive OR brain OR mental)
#3 Topic=(random* ORplaceboOR “dou-
ble-blind*” OR trial OR “control group*”
OR “single-blind*”)
#4 #3 AND #2 AND #1
#5 Topic=(#4)
Databases=SCI-EXPANDED, SSCI, CPCI-
S Timespan=2009-2011
June 2010: 206
June 2011: 174
April 2012: 251
LILACS (BIREME) “omega 3”ORPUFAOR“fatty acid$”OR
eicosapentanoic OR docosahexanoic OR
“linseed”OR “fish oil$” [Words] and brain
OR cognition OR cognitive OR men-
tal [Words] and random$ OR trial$ OR
group$ OR placebo$ [Words]
June 2010: 6
June 2011: 6
April 2012: 11
CENTRAL (The Cochrane Library) #1 MeSH descriptor Fatty Acids, Omega-
3 explode all trees
#2 omega-3 OR “omega 3”
#3 “polyunsaturated fatty acid*”
#4 PUFA
#5 “unsaturated fatty acid*” OR “essential
fatty acid*”
#6 EFA OR “eicosapentanoic acid”
#7 MeSH descriptor Eicosapentaenoic
Acid explode all trees
#8 EPA OR “ethyl-eicosapentanoic acid”
OR E-EPA
#9 “docosahexanoic acid*”
#10 DHA
#11 “docosapentanoic acid*” OR DPA
#12 “alpha-linolenic acid*” OR ALA
June 2010: 53
June 2011: 54
April 2012: 48
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#13 “fish oil” OR “n-3 fatty acid*” OR
“long chain fatty acids”
#14 “primrose oil” OR “linseed oil” OR
“oily fish” OR “flaxseed oil”
#15 (#1 OR #2 OR #3 OR #4 OR #5 OR
#6 OR #7 OR #8 OR #9 OR #10 OR #11
OR #12 OR #13 OR #14)
#16 participant* NEAR/2 (healthy or old*
or elderly or aged or senior)
#17 adult NEAR/2 (old* or elderly or aged
or senior)
#18 “healthy persons”
#19 cognit* or “prevent* dementia*”
#20 (#16 OR #17 OR #18 OR #19)
#21 (#15 AND #20)
#22 (#21), from 2009 to 2011
ClinicalTrials.gov cognition OR cognitive OR brain OR
mentalORdementia | Interventional Stud-
ies | omega OR fish OR linseed OR fatty
acid OR fatty acids OR PUFA OR eicos-
apentanoic OR docosahexanoic OR DHA
| updated from 01/01/2009 to 06/17/2011
June 2010: 76
June 2011: 20
April 2012: 14
ICTRP (WHO portal) cognition OR cognitive OR brain OR
mentalORdementia | Interventional Stud-
ies | omega OR fish OR linseed OR fatty
acid OR fatty acids OR PUFA OR eicos-
apentanoic OR docosahexanoic OR DHA
| updated from 01/01/2009 to 17/06/2011
June 2010: 27
June 2011: 20
April 2012: 17
Total June 2010: 615
June 2011: 517
April 2012: 569
Total after de-duplication and first-assess June 2010: 36
June 2011: 76
April 2012: 17
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WH A T ’ S N E W
Last assessed as up-to-date: 6 April 2012.
Date Event Description
14 August 2012 Amended Typographical correction to heading of analysis 3.1
H I S T O R Y
Protocol first published: Issue 3, 2005
Review first published: Issue 1, 2006
Date Event Description
30 April 2012 New citation required and conclusions have changed The search for studies is updated to 6 April 2012.
Three studies are included; the results and conclusions
have changed. The authors of the review have changed
6 April 2012 New search has been performed The search is updated to 6 April 2012.
6 November 2008 Amended Converted to new review format.
12 November 2005 New citation required and conclusions have changed Substantive amendment.
C O N T R I B U T I O N S O F A U T H O R S
Contribution to the first published version (2006):
Wee-Shiong Lim led the review team, screened the search for studies, and took the lead in drafting the manuscript. Julie Gammack
and Jan Van Niekerk assisted in searching for studies and sought to identify studies for inclusion by screening the search results. All
authors provided intellectual input into the final version of the review.
Contribution to the 2012 update:
Emma Sydenham (ES),Wee-Shiong Lim (W-S L), and AlanDangour (AD) screened the search results and selected studies for inclusion.
AD contacted experts in the field, sought additional data from included study investigators, and re-wrote the Background section. ES
contacted omega-3 manufacturers for additional data; the data were reviewed by AD and W-S L. ES extracted data from the study
reports, entered the data into RevMan, assessed the risk of bias in included studies, undertook the analysis, and updated the text of the
review; W-S L checked for accuracy. All authors contributed to the final version of the manuscript. No sources of support are listed as
all authors contributed to this review in their own time.
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D E C L A R A T I O N S O F I N T E R E S T
AlanDangour is the principal investigator of Dangour 2010 (theOlder People And n-3 Long-chain polyunsaturated fatty acids (OPAL)
study).
ES and W-S L: None known.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
The methods of the review were updated to comply with the most recent version of the Cochrane Handbook for Systematic Reviews
of Interventions (Version 5.1 March 2011) and the Cochrane Collaboration’s Methodological Expectations of Cochrane Intervention
Reviews criteria (November 2011).
The analysis of secondary outcomes was changed from mean change from baseline to difference between intervention groups at final
follow-up (Handbook section 7.7.3.1).
The secondary outcomes health-related quality of life, depression, and anxiety which are listed in the protocol have been removed from
this review. These outcomes have been assessed elsewhere (Appleton 2010).
N O T E S
Future updates of this review will include participants age 50 years and over.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Cognition Disorders [∗prevention & control]; Dementia [∗prevention & control]; Fatty Acids, Omega-3 [∗therapeutic use]; Random-
ized Controlled Trials as Topic
MeSH check words
Aged; Aged, 80 and over; Female; Humans; Male
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